These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Kuchay MS; Choudhary NS; Mishra SK; Misra A Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD; Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212 [TBL] [Abstract][Full Text] [Related]
31. CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE. Virović Jukić L; Grgurević I; Mikolašević I; Filipec Kanižaj T; Milić S; Mrzljak A; Premužić M; Hrstić I; Knežević-Štromar I; Ljubičić N; Ostojić R; Stojsavljević Shapeski S; Amerl-Šakić V; Marković NB; Rađa M; Soldo D; Sobočan N; Lalovac M; Puljiz Ž; Podrug K; Ladić D Acta Clin Croat; 2021 Dec; 60(Suppl 2):36-52. PubMed ID: 35528151 [TBL] [Abstract][Full Text] [Related]
32. Are statins 'IDEAL' for non-alcoholic fatty liver disease? Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654 [TBL] [Abstract][Full Text] [Related]
34. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Godinez-Leiva E; Bril F Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841 [TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Basu R; Noureddin M; Clark JM Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582 [TBL] [Abstract][Full Text] [Related]
36. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ; J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290 [TBL] [Abstract][Full Text] [Related]
37. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Ferguson D; Finck BN Nat Rev Endocrinol; 2021 Aug; 17(8):484-495. PubMed ID: 34131333 [TBL] [Abstract][Full Text] [Related]
38. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Lomonaco R; Chen J; Cusi K Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186 [TBL] [Abstract][Full Text] [Related]
39. [Prevalence and harm of nonalcoholic fatty liver disease]. Shao YL; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):10-13. PubMed ID: 30685917 [TBL] [Abstract][Full Text] [Related]